Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-16
2007-10-16
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S012200, C424S085100, C530S350000, C536S023500, C435S069100, C435S320100, C435S252330, C435S361000, C435S365000
Reexamination Certificate
active
09898234
ABSTRACT:
The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
REFERENCES:
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4560649 (1985-12-01), Saxena et al.
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4931544 (1990-06-01), Katre et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4966888 (1990-10-01), Saxena et al.
patent: 5089261 (1992-02-01), Nitecki et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5153265 (1992-10-01), Shadle et al.
patent: 5162430 (1992-11-01), Rhee et al.
patent: 5214131 (1993-05-01), Sano et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5344915 (1994-09-01), LeMaire et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5633145 (1997-05-01), Feldmann et al.
patent: 5665859 (1997-09-01), Wallach et al.
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5712155 (1998-01-01), Smith et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5811261 (1998-09-01), Wallach et al.
patent: 5863786 (1999-01-01), Feldmann et al.
patent: 5981701 (1999-11-01), Wallach et al.
patent: 6294352 (2001-09-01), Hauptmann et al.
patent: 03910323 (1988-03-01), None
patent: 3913101.7 (1989-04-01), None
patent: 0920282.8 (1992-08-01), None
patent: 0154316 (1985-09-01), None
patent: 0154316 (1985-09-01), None
patent: 0162699 (1985-11-01), None
patent: 0225579 (1987-06-01), None
patent: 0247860 (1987-12-01), None
patent: 0259863 (1988-03-01), None
patent: 0 308 378 (1989-03-01), None
patent: 0334165 (1989-09-01), None
patent: 0393438 (1990-10-01), None
patent: 0398327 (1990-11-01), None
patent: 0412486 (1991-02-01), None
patent: 0417563 (1991-03-01), None
patent: 0418014 (1991-03-01), None
patent: 0422339 (1991-04-01), None
patent: 0433900 (1991-06-01), None
patent: 0512528 (1992-11-01), None
patent: 0526905 (1993-02-01), None
patent: 0308378 (1994-11-01), None
patent: 2218101 (1989-11-01), None
patent: 2246569 (1992-02-01), None
patent: WO90/13575 (1990-11-01), None
patent: WO91/03553 (1991-03-01), None
patent: WO92/01002 (1992-01-01), None
patent: WO92/01474 (1992-02-01), None
patent: WO92/07076 (1992-04-01), None
patent: WO92/13095 (1992-08-01), None
patent: WO92/15682 (1992-09-01), None
patent: WO92/16221 (1992-10-01), None
patent: WO94/06476 (1994-03-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
The Cytokine Facts Book, Second Edition, Academic Press, Fitzgerald et al. editors, p. 478.
Olsson et al., Eur. J. Haematol., Mar. 1989, vol. 42, pp. 270-275.
Corti et al., Journal of Interferon and Cytokine Research, vol. 15, pp. 143-152 (1995).
Anderson et al., “Quantitative Filter Hybridisation,”Nucleic Acid Hybridization: A Practical Approachpp. 73-111 (Hawes et al., eds., 1985).
Aggarwal et al., “Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon,”Nature318:665-67 (1985).
Baglioni et al., “Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition,”J. Biol. Chem. 260:13395-97 (1985).
Bakouche et al., “Plasma membrane-associated tumor necrosis factor. A non-integral membrane protein possibly bound to its own receptor,”J. Immunol. 140:1142-47 (1988).
Beutler et al., “The Biology of Cachectin/TNF-A Primary Mediator of the Host Response”, Ann. Rev. Immunol. 1989, 7:625-55.
Binkert et al., “Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2),”EMBO J. 8:2497-502 (1989).
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science247:1306-10 (1990).
Brennan et al., “Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis,”Lancet2:244-47 (1989).
Brockhaus, M. et al., Proc. Natl. Acad. Sci. USA 87:3127-3131 (1990).
Capaldi et al., “Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis,”Biochem. Biophys. Res. Commun. 74:425-33 (1977).
Colletti et al., “The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion,”Transplantation49:268-72 (1990).
Creasy, A. et al., Proc. Natl. Acad. Sci. USA 84:3293-3297 (1987).
Dayer et al., “Purification and Characterization of Human Tumor Necrosis Factor a Inhibitor,”Chemical Abstracts113(38760n):454 (1990).
Dembic et al., “Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences,”Cytokine2:231-37 (1990).
Engelmann et al., “Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine,” The Journal of Biological Chemistry, vol. 265. No. 3 Issue of Jan. 25, pp. 1531-1536, 1990.
Engelmann et al., “Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity,”J. Biol. Chem. 265:14497-504 (1990).
Espevik et al., “Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor,”J. Exp. Med. 171:415-26 (1990).
Evans, “The steroid and thyroid hormone receptor superfamily,”Science240:889-95 (1988).
Frohman et al., “Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer,”Proc. Natl. Acad. Sci. U. S. A. 85:8998-9002 (1988).
Gatanaga et al., Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin . . . , Proc. Natl. Acad. Sci. USA 87:8781-8784 (1990).
Goodson et al., “Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site,” Bio Technology 8:343-346 (1990).
Goodwin et al., “Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor,”Mol. Cell. Biol. 11:3020-26 (1991).
Gray et al., “Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein,”Proc. Natl. Acad. Sci. U. S. A. 87:7380-84 (1990).
Grizzard et al., “Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus,”J. Clin. Endocrinol. Metab. 58:535-43 (1984).
Hale et al., “Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed inE. Coli,” J. Cell Biochem. Suppl. 15F:113(1991).
Hass et al., “Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibrobla
Hauptmann Rudolf
Himmler Adolf
Maurer-Fogy Ingrid
Stratowa Christian
Amgen Inc.
O'Hara Eileen B.
LandOfFree
Method of ameliorating the harmful effects of TNF using a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of ameliorating the harmful effects of TNF using a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of ameliorating the harmful effects of TNF using a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3899666